Highly sensitized patients experience reduced access to transplantation. In an effort to increase access, some transplant programs are willing to accept added clinical risk for such patients by transplanting across a weak DSA in the face of a negative or weakly positive crossmatch. Hence, our aim was to quantify the theoretical impact of raising MFI cutoffs for moderately and highly sensitized patients thereby reducing the cPRA and, theoretically, increasing their chances of a deceased donor offer.Sixty-three active wait list candidates with a cPRA >50% (based on a 2,000 MFI cutoff) were selected for this study. Each patient’s unacceptable antigens were reassessed based on MFI cutoffs of 3,000 and 5,000. For each candidate, the % change in cPRA between current value (@ MFI = 2000) and cPRA at 3000 and 5000 MFI was calculated.Among the 63 patients, only 16% experienced a significant drop in cPRA (>20% decrease) when increasing the MFI cutoff to 3000. When the cutoff was increased to 5000, 22% exhibited a significant decrease. At an MFI cutoff of 3000, patients with <20% drop in cPRA had an average initial cPRA of 89% while patients with >20% decrease had an average cPRA of 70%. At a cutoff of 5000, patients with <20% drop in cPRA had an average cPRA of 89% and patients with >20% cPRA decrease had an average cPRA of 69%.[Table 1]Based on the results of this study, raising the MFI threshold does not have a significant impact for the majority of highly sensitized patients (eg: cPRA >80%). However, for some patients with initial cPRA (@ 2,000 MFI) <70% their access may be improved by this approach. Given the known increased risk for early AMR when low level DSA is present, the decision to raise the MFI threshold in an effort to increase access should be a programmatic decision and applied on a patient by patient basis.